Hologic, Inc. (NASDAQ:HOLX) Stock Position Decreased by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp lowered its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 33.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 194,088 shares of the medical equipment provider's stock after selling 99,302 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned 0.09% of Hologic worth $13,992,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. General Partner Inc. purchased a new position in Hologic during the fourth quarter worth about $26,000. Groupama Asset Managment lifted its holdings in shares of Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock worth $27,000 after acquiring an additional 2,999 shares during the period. Venturi Wealth Management LLC boosted its position in shares of Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after acquiring an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 260 shares during the period. Finally, Smartleaf Asset Management LLC increased its position in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Remove Ads

Hologic Stock Performance

Shares of NASDAQ HOLX traded down $0.85 during mid-day trading on Wednesday, hitting $60.54. The company had a trading volume of 318,758 shares, compared to its average volume of 2,405,193. Hologic, Inc. has a 12 month low of $60.03 and a 12 month high of $84.67. The stock has a market cap of $13.58 billion, a price-to-earnings ratio of 19.10, a PEG ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm's 50 day simple moving average is $64.90 and its two-hundred day simple moving average is $72.97.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on HOLX. Citigroup cut their target price on Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. BNP Paribas raised shares of Hologic to a "strong-buy" rating in a research report on Tuesday, December 10th. Royal Bank of Canada cut their target price on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a research note on Thursday, February 6th. Jefferies Financial Group started coverage on shares of Hologic in a research report on Tuesday, December 10th. They set a "hold" rating and a $85.00 price target for the company. Finally, Leerink Partners lowered Hologic from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.